Clinical trials
HIV clinical trials
Below are recruiting hiv clinical trials, each written for real people, not researchers. We’re tracking 583 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07772791Recruiting
Online study on digital tools for HIV prevention and treatment in Brazil
This study tests online programs to help people who are at higher risk for HIV get prevention or treatment. It aims to see if digital tools can improve access to and use of HIV medications.
Rio de Janeiro, Rio de JaneiroAges 18 years+ - NCT07757802RecruitingPhase 1
HIV vaccine nanoparticle and mRNA booster for healthy adults
This study tests a new HIV vaccine that uses tiny particles (nanoparticles) and an mRNA booster — similar to some COVID vaccines. The goal is to see if it is safe and helps your body fight HIV. It's for healthy adults who do not have HIV.
San Francisco, CaliforniaAges 18–55 - NCT07751978Recruiting
HIV care support for women who inject drugs
This study tests a program to help women living with HIV who also inject drugs stay engaged in their HIV care. It aims to reduce stigma and improve health outcomes.
Kyiv, Kyiv OblastAges 18 years+ - NCT07745530Recruiting
How platelets affect HIV reservoirs in the blood
This study looks at how platelets (small blood cells that help with clotting) might influence the hidden HIV that remains in your body even when your viral load is undetectable. The goal is to understand why some people's immune systems don't fully recover despite effective HIV treatment.
TourcoingAges 18 years+ - NCT07737340Recruiting
Metabolic liver disease in new HIV patients
This study looks at liver health in people newly diagnosed with HIV, before they start HIV treatment. It aims to understand early changes in the liver related to metabolism.
Ankara, AnkaraAges 18 years+ - NCT07732660Recruiting
Building skills and reducing stigma for young people with HIV in Zambia
This trial helps young people aged 18 to 24 living with HIV in three districts of Zambia. It aims to reduce stigma and build job skills to improve their lives.
Lusaka, Lusaka ProvinceAges 18–24 - NCT07728123Recruiting
Screen2Prevent for young people in the ED
This trial is testing a prevention strategy for young people who come to the emergency department. It aims to find better ways to screen and prevent health problems early on.
Tampa, FloridaAges 14–24 - NCT07725042Recruiting
HIV infection study in Hong Kong for newly diagnosed adults
This study looks at people newly diagnosed with HIV in Hong Kong. It aims to understand patterns of infection to improve care.
North PointAges 18 years+ - NCT07719491RecruitingPhase 1
Study of GS-0415 in People with HIV
This study tests a new drug, GS-0415, for people with HIV. The study will see if this drug can help control the virus. Participants will continue taking their regular HIV medication.
Los Angeles, CaliforniaAges 18–65 - NCT07708727RecruitingPhase 2/Phase 3
Injectable HIV treatment vs daily pill for new patients
This trial tests a new injectable HIV treatment (GS-3242 plus lenacapavir) compared to the daily pill Biktarvy for people just starting HIV therapy. If you qualify, you would receive shots every few weeks instead of taking a daily pill.
Torrance, CaliforniaAges 18 years+ - NCT07707778Enrolling by invitationPhase 4
Tirzepatide for Weight and Aging in People with HIV
This trial tests whether a weight-loss medicine called tirzepatide can slow biological aging and improve metabolism in people with HIV who are already on effective treatment. It may help you reduce weight and possibly reverse some signs of aging.
TaipeiAges 18 years+ - NCT07706634Recruiting
Helping people with HIV stay in care
This study tests ways to help people living with HIV in Indonesia stay engaged in their care. It may help you if you want extra support to keep up with your appointments and treatment.
Depok, West JavaAges 18 years+ - NCT07698600RecruitingPhase 1
Safety test of a new HIV vaccine in adults with or without HIV
This study tests a new RNA-based vaccine called BNT168 to see if it is safe and how the body responds to it. It is for healthy adults with or without HIV, and those with HIV will pause their regular treatment for a while during the study.
Houston, TexasAges 18–50 - NCT07704164RecruitingPhase 2
Colchicine to lower heart artery swelling in HIV
This trial tests if colchicine, a medicine for inflammation, can reduce swelling in the heart arteries of people with HIV. It may help lower the risk of heart problems in those already on a statin or similar medication.
BarcelonaAges 50 years+ - NCT03684655RecruitingPhase 2
PET-MR scan study of immune activity in people with HIV
This Phase 2 study uses a special whole-body scan (PET-MR) to measure immune activity in people living with HIV. It may help researchers understand how well the immune system responds and how to better track HIV-related inflammation.
San Francisco, CaliforniaAges 18 years+ - NCT07683117Recruiting
PEP/PrEP through pharmacist prescribing (PEPPI)
This study looks at how well pharmacists can provide PEP and PrEP (HIV prevention pills) using a special software called PEPPI. It aims to make it easier and faster for people to get these medicines.
Del Mar, CaliforniaAges 18 years+ - NCT07682961RecruitingPhase 3
Study of new HIV injection vs. standard injectables
This phase 3 trial tests a new long-acting, injectable two-drug combination (lenacapavir + teropavimab + zinlirvimab) vs. another injectable combo (cabotegravir + rilpivirine) for people whose HIV is already well-controlled on daily oral meds. It aims to see if the new combo can keep the virus under control with fewer injections.
San Francisco, CaliforniaAges 18 years+ - NCT07683000RecruitingPhase 3
Study of three HIV drugs for adults with controlled HIV
This trial tests a new combination of three medications, lenacapavir, teropavimab, and zinlirvimab, for people with HIV who currently have undetectable virus levels on a stable oral treatment. The goal is to see if these drugs can keep the virus suppressed, possibly allowing a simpler treatment plan.
Berkeley, MichiganAges 18 years+ - NCT07678268RecruitingPhase 4
Comparing HIV treatments for virologically suppressed men
This trial tests if a two-drug HIV regimen (darunavir/cobicistat plus lamivudine) works as well as a three-drug regimen (darunavir/cobicistat plus tenofovir alafenamide/emtricitabine) in men whose HIV is already suppressed. The goal is to find a simpler, effective option that may have fewer side effects.
Mexico City, Mexico CityAges 18 years+ - NCT07672717RecruitingPhase 1
Cabotegravir and hormone interaction study for HIV prevention
This study tests how a long-acting injectable HIV prevention drug (cabotegravir) works in people who also use hormone therapy (like birth control or gender-affirming hormones). The goal is to see if the hormones affect how well the drug prevents HIV. If you are HIV-negative, use hormones, and meet other health criteria, you may be able to join.
Baltimore, MarylandAges 19 years+ - NCT07650916RecruitingPhase 3
A study of two ultra-long-acting HIV shots
This trial tests a new ultra-long-acting injectable combination of cabotegravir and rilpivirine for people with HIV who already have the virus under control. It aims to see if these shots can keep the virus suppressed with fewer doses.
Phoenix, ArizonaAges 12 years+ - NCT07643948Recruiting
How HIV Treatment Changes Affect Drug Resistance
This study follows people with HIV whose virus is well-controlled on current medications to understand how switching to a different HIV drug regimen affects the virus's ability to resist those drugs. The goal is to help doctors choose the safest treatment switches.
Hong Kong, Hong KongAges 18 years+ - NCT07637877RecruitingPhase 2
Treatments to boost immune recovery in HIV
This study tests new treatments to help people with HIV who have low CD4 counts despite antiretroviral therapy. It aims to improve immune function and reduce the risk of infections.
Beijing, Beijing MunicipalityAges 18–60 - NCT06717581Recruiting
Drug interaction study for older people with HIV
This study looks at how other medicines you take for conditions like high blood pressure, diabetes, or cholesterol might interact with your HIV medication (Biktarvy) if you are 60 or older. The goal is to learn how to better manage your overall health.
BolognaAges 18 years+
Hear when a new HIV trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for hiv?
- Yes. Clin2 currently lists 583 recruiting hiv studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a hiv trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a hiv trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.